NICE recommended semaglutide 2.4 mg (TA875, 2023) for use within specialist Tier 3 weight management services in adults with a BMI of 35 kg/m (or 32.5 kg/m in people of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family background) with at least one weight-related comorbidity, or a BMI of 3034.9 kg/m in specific circumstances
For pharma planning teams, the implication is that obesity is now a multi-endpoint, multi-mechanism therapeutic area
Patients taking multiple medications should have their entire prescription reviewed to identify potential contributors
It is approved in different doses under brand names like Wegovy and Ozempic , depending on whether it is used for weight loss or for type 2 diabetes
14 Also, there were no changes in the lipogenesis regulator LPL (lipoprotein lipase) or the endothelial factor CD31 (cluster of differentiation 31)/ PECAM1 (platelet/endothelial cell adhesion molecule 1, see Table 1)